Skip to main content
Caplight Logo









Mammoth Biosciences

Mammoth Biosciences

Private
Brisbane, CaliforniaHealthcare & Life Scienceshttps://mammoth.bio/

Last Round

Series D

Sep 9, 2021

Est. Valuation

$1B

Total Funding Raised

$287.6M

Company Overview

Mammoth Biosciences is a biotechnology company that develops long-term curative therapies and decentralized precision diagnostics using proprietary ultracompact CRISPR proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

CRISPRgene editingmolecular diagnosticsCRISPR techCas enzymesprotein discoverynext-gen CRISPRCRISPR diagnosticsbiotech platformAI-native biotechin-vivo gene editingmetagenomic discoverybiosurveillancebiodefensegene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mammoth Biosciences Comparables

Compare Mammoth Biosciences with similar companies based on industry and business-model similarity.

Mammoth Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Metagenomi
85%
Arbor Biotechnologies
82%
Scribe Therapeutics
77%

Mammoth Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 9, 2021
Series CNov 1, 2020
GrantJul 30, 2020
Series BJan 30, 2020
Series AJul 31, 2018
Seed
Nov 1, 2017

Key People

Founding team and executive leadership

Janice Chen

Co-founder CTO

Founding Team

d sw

Chief Executive Officer

Executive Team

Trevor Martin

Co-founder, Chief Executive Officer

Founding Team

Trevor Martin

Co-Founder And CEO

Founding Team

Mammoth Biosciences Investors

Notable investors and investment history

Mammoth Biosciences investors
InvestorRounds
Redmile GroupSeries C, Series D
NFXSeries A, Series B, Series D, Seed, Pre Seed
Pacific 8 VenturesSeries B
NIH RADxGrant
Plum Alley InvestmentsSeries B
StepStone GroupSeries D
Sixth Street PartnersSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Preclinical data for MB-111 to be presented at industry congress.

  • Oct 1, 2025

    Presenting at the European Society of Gene & Cell Therapy Congress.

Mammoth Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mammoth Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mammoth Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrisbane, California
Employee Range160
Year Founded2017
Last FundingSep 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?